Western import of 15% tariff on Western imports from the United States:

Medical Network April 3 news Ministry of Finance website news, approved by the State Council, the State Council Customs Tariff Commission decided to part of the import of goods from the United States to suspend tariff reduction obligations, since April 2, 2018 implementation.

The reporter noted that the specific product list tentatively contains 7 categories and 128 tax items. medicine In the field, reference is made to fresh, cold, dried or dried American ginseng, other fresh ginseng and other cold, frozen or dried ginseng, subject to a 15% tariff.

During the interview, a senior expert in the field of pharmaceutical import and export of American ginseng and the possible impact of the participation of fresh people on tariffs said to reporters: 'Overall, it should have little effect on China's import and export trade of Chinese medicine, and it has a slight impact on American ginseng. Although the United States is an important market for the import of American ginseng, it is not the largest market. Canada is the main channel for the import of American ginseng.

The information of Chinese herbal medicine Tiandiwang pointed out that after large-scale introduction of American ginseng in 1975, it began to promote the cultivation of American ginseng in Jilin, Liaoning, Heilongjiang, Shaanxi, Beijing, Shandong and other provinces and cities. However, since the price fell sharply in 2015, planting The area has been reduced to varying degrees.

In recent years, American ginseng has been affected by factors such as ecological environment, cultivation and processing technologies, and market sales. The planting areas have become increasingly concentrated. The current largest production area is Jilin, followed by Shandong, Beijing, Heilongjiang, and relatively few in Heilongjiang. The output has been very small, of which the production of American ginseng in Jilin production area accounts for more than half of the total output.

However, an American ginseng field researcher suggested that American ginseng planting is also at the bottom of the value chain. The American ginseng industry needs to break ice. To climb to the top, it is necessary to use good seeding as a stepping stone and deep processing as a golden key. Some experts also suggested the establishment of a retrospective system for the circulation of Chinese medicine through the Ministry of Commerce to further strengthen the management and control of the entire American ginseng chain and establish higher industry standards and quality levers.

With regard to the recent move in the American Ginseng market, the Chinese herbal medicine world card pointed out that the current U.S. ginseng market has accelerated the pace of movement of goods, merchants have stable stocks, and the prices are stable. The price of U.S. ginseng domestic long-term products (per kilogram, the same below) is 600~. Between RMB 650 and RMB 700 to RMB 750 for short products, RMB 1100 to RMB 1200 for imported short grain products, RMB 2200 to RMB 2300 for small grain products, and RMB 700 to RMB 750 for medium chips.

After the proposed addition of tariff assessment opinions, there are also some viewpoints in the industry that may affect the sales of imported American ginseng in China. To a certain extent, it may boost domestically produced American ginseng and ginseng market. Some analysts pointed out that China has to switch to importing Canada. American ginseng. Canada's American ginseng is far from satisfying the market demand of our country, our country's related industry will usher in good.

At present, listed companies involved in American ginseng and ginseng distribution include Yisheng Pharmaceutical, Zixin Pharmaceutical, and Kangmei Pharmaceutical.

For example, Yisheng Pharmaceutical has conducted comprehensive three-dimensional development of ginseng and American ginseng. According to statistics, Yisheng Pharmaceutical Co., Ltd. owns 12,000 mu of ginseng planting base and annually produces 1,632 tons of ginseng. Looking at the 2017 annual earnings report released by the growing pharmaceutical company , Achieved operating income of 1.038 billion yuan, an increase of 10.51%; Realize net profit attributable to shareholders of listed companies was 600.338 million yuan, an increase of 354.99%. For growth reasons, Yisheng Pharmaceutical said that increase the promotion of ginseng related products This is one of the reasons for the increase in sales revenue in the current period.

Zixin Pharmaceutical has established four ginseng production and processing bases around the main ginseng production areas in Jilin Province. At present, there are 137 foods in the region. cosmetic , Health products The ginseng series product varieties in the company were successfully developed, with the first batch of approved 12 varieties, the second batch of 29 batches, and a total of 41 varieties approved for pilot production. Its newly released 2017 annual results are equally eye-opening, opening in 2017. The total revenue increased by 61.82% over the previous period, mainly due to the sales revenue of OTC products of proprietary Chinese medicines, and the sales revenue of ginseng products increased over the previous period. The operating profit increased by 163.57% from the previous period, which was mainly due to the increase in sales revenue of ginseng products and the gross profit rate. Higher products account for a larger proportion of ginseng sales revenue.

Kangmei Pharmaceuticals has a large area of ​​ginseng cultivation base. In addition, the Ministry of Commerce direct marketing management information shows that Kangmei Pharmaceutical's approved direct sales products are Kangmei-branded American ginseng capsules. The information shows that the American ginseng is from Kangmei Pharmaceutical. Planting base, product production also comes from Kangmei Pharmaceutical drug production line.

It is worth mentioning that for China's industrial sector, it has always been in the stage of high output, low production value, and low degree of industrialization. The competitiveness of the brand is relatively weak. Even so far, there is still no one that can compete with foreign brands such as Zhengguanzhuang Ginseng. The big brands. Kangmei Pharmaceutical said earlier that domestic industrial development must be awakened strategically. First, at the national level, we must establish and improve the access system for the Chinese ginseng market in terms of cultivation, production, and quality control. Breeding faucet enterprise , Establishing its own brand to enhance the competitiveness of China’s ginseng in the international market. In terms of product structure, it is necessary to vigorously support the construction of the entire industry chain of ginseng, and to achieve the extension of low-end to high-end production from primary processing to end-consumer production. Policy guidance strengthens the terminal link and activates the market demand for ginseng products.